Rationale and early clinical data on IL-17 blockade in psoriasis.
about
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A TherapiesInterleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseasesCytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial.Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.Clinical potential of brodalumab in the management of psoriasis: the evidence to date.
P2860
Rationale and early clinical data on IL-17 blockade in psoriasis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rationale and early clinical data on IL-17 blockade in psoriasis.
@ast
Rationale and early clinical data on IL-17 blockade in psoriasis.
@en
type
label
Rationale and early clinical data on IL-17 blockade in psoriasis.
@ast
Rationale and early clinical data on IL-17 blockade in psoriasis.
@en
prefLabel
Rationale and early clinical data on IL-17 blockade in psoriasis.
@ast
Rationale and early clinical data on IL-17 blockade in psoriasis.
@en
P2093
P2860
P1476
Rationale and early clinical data on IL-17 blockade in psoriasis.
@en
P2093
Amanda H Champlain
Kenneth B Gordon
Steven M Nwe
P2860
P304
P356
10.1586/1744666X.2013.811034
P577
2013-07-01T00:00:00Z